|
Dr. Shochat has over 22 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. At Immunomedics, he led the team that developed the approved in vivo tumor-imaging reagent CEA-Scan. He joined American Cyanamid in 1989 to establish their biotechnology development capability and led the team that developed the first approved antibody-drug conjugate, Mylotarg. In 1995, Dr. Shochat became the first employee of Coulter Pharmaceutical, where he established a �virtual development activity� managing the outsourcing of process development, manufacturing and quality systems by recruiting key experts in each area. He designed and established the process, formulation, and facility to commercially radiolabel the anti-B1 antibody at a 55 curie scale. The lead product from this work is Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin�s Lymphoma approved by the FDA in 2003. | 